Treatment Overview
The Bevacizumab Intravitreal Injection Program in Korea is a specialized retinal treatment that uses Bevacizumab (Avastin®), an anti-VEGF (vascular endothelial growth factor) medication, to reduce abnormal blood vessel growth and retinal swelling. The therapy is widely used for conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and other retinal vascular diseases.
Korea is internationally recognized for its advanced approach to intravitreal injection care, integrating:
- High-definition OCT imaging for precise retinal assessment
- Customized anti-VEGF dosing strategies
- AI-based macular thickness and fluid analysis
- Ultra-fine needle techniques for painless injections
- Sterile operating room (OR) injection suites
- Rapid monitoring systems for post-injection safety
- International-standard treatment protocols following global clinical guidelines
This program ensures accurate disease monitoring, effective vision preservation, and optimized treatment outcomes across a wide range of retinal diseases.
Purpose & Benefits
Purpose
- Reduce retinal swelling caused by abnormal blood vessel leakage
- Stop the growth of harmful neovascularization
- Improve or stabilize vision in patients with retinal vascular disease
- Control macular edema using OCT-guided treatment intervals
- Prevent further vision loss
- Provide cost-effective anti-VEGF therapy with excellent outcomes
Benefits
- Rapid reduction in retinal fluid and swelling
- High success rates for vision stabilization
- Painless, quick, and minimally invasive procedure
- OCT-guided dosing ensures precise, personalized treatment
- Consistent improvement in macular thickness
- Lower cost compared to other anti-VEGF treatments
- Excellent safety record and strong international clinical evidence
Ideal Candidates
The Bevacizumab Intravitreal Injection Program in Korea is ideal for:
- Patients with wet age-related macular degeneration (wet AMD)
- Individuals with diabetic macular edema (DME)
- Patients with retinal vein occlusion (BRVO or CRVO)
- Individuals with choroidal neovascular membranes
- Patients displaying subretinal or intraretinal fluid on OCT
- Those undergoing long-term anti-VEGF therapy requiring reliable monitoring
- Patients seeking a cost-effective but effective retinal treatment option
Possible Risks & Complications
Bevacizumab intravitreal injections are generally safe when performed by experienced retinal specialists. However, potential risks include:
- Mild eye redness or irritation
- Temporary floaters
- Minor subconjunctival hemorrhage
- Transient pressure elevation
Rare but serious risks:
- Infection (endophthalmitis)
- Retinal detachment
- Intraocular inflammation
- Cataract from accidental contact with the lens
Korean clinics minimize these risks with:
- Sterile OR-level injection rooms
- Pre- and post-procedure OCT imaging
- Strict disinfection and injection protocols
- Ultra-fine needle techniques
- Same-day follow-up options when needed
Related Treatment Options
- Aflibercept (Eylea®) Injection
For patients needing stronger fluid-resolving effects. - Ranibizumab (Lucentis®) Injection
FDA-approved alternative with high safety profile. - Faricimab
Dual inhibitor for longer treatment intervals. - Steroid Implants (Ozurdex®)
Ideal for chronic macular edema or non-responders. - Laser Photocoagulation
For select diabetic and vascular disease cases.
Treatment Process in Korea
Step 1 – Baseline Retina Assessment
OCT, fundus photography, and vision testing to evaluate macular swelling and neovascular activity.
Step 2 – Preparation & Sterile Protocol
The eye is cleaned, numbed, and prepared under sterile conditions.
Step 3 – Intravitreal Bevacizumab Injection
A micro-needle delivers the medication into the vitreous cavity—quick, painless, and completed within seconds.
Step 4 – Immediate Post-Monitoring
Intraocular pressure and eye condition are checked.
Step 5 – OCT-Guided Follow-Up
Follow-up imaging determines treatment interval and response.
Program Duration: 10–20 minutes
Setting: Sterile ophthalmic injection suite or minor OR
Recovery & After-Care
After-Care Guidelines
- Avoid touching or rubbing the eye
- Use prescribed antibiotic drops if given
- Mild irritation or tearing is normal for 1–2 days
- Report sudden vision loss, pain, or numerous floaters
- Attend follow-up appointments for OCT monitoring
Recovery Timeline
- Immediate: Vision returns to normal within hours
- 1–2 Days: Mild irritation resolves
- 1–4 Weeks: OCT shows fluid reduction after ongoing treatment
- Long-Term: Regular injections maintain stable or improved vision
Results & Longevity
Expected Results
- Reduction of macular fluid visible on OCT
- Stabilized or improved visual acuity
- Decreased retinal swelling
- Slowed or halted progression of wet AMD or DME
- Long-term preservation of central vision
Longevity
- Effects last 4–8 weeks depending on condition
- Long-term therapy provides stable anatomical and functional outcomes
- Treatment intervals become personalized based on OCT response
- Ongoing injections prevent recurrence of fluid and neovascularization
Why Korea Is a Top Destination
- Highly trained retina specialists with extensive experience
- Use of OCT, angiography, and AI analysis for precise follow-up
- Timely, efficient treatment systems for monthly or PRN regimens
- International-standard safety protocols
- Cost-effective injection options
- Modern clinics equipped with dedicated sterile injection rooms
Unique Korean Innovations
- AI-assisted macular fluid quantification
- Customized injection intervals using predictive OCT algorithms
- Ultra-fine, low-pain injection techniques
- High-speed retina imaging systems for instant analysis
- Integrated treatment platforms combining OCT, fundus imaging, and angiography
These innovations make Korea’s
Bevacizumab Intravitreal Injection Program
one of the most efficient, safe, and technologically advanced retinal treatment systems available worldwide.
Cost Range (Indicative Estimate)
| Program Package | Price (KRW) | Approx. USD | Inclusions |
|---|---|---|---|
| Basic Bevacizumab Injection | ₩150,000 – ₩300,000 | ~$110 – $230 | Injection + sterile suite |
| Bevacizumab Injection + OCT | ₩250,000 – ₩450,000 | ~$190 – $340 | Injection + OCT + IOP check |
| Comprehensive Anti-VEGF Monitoring Plan | ₩500,000 – ₩1,000,000+ | ~$380 – $750+ | Full evaluation + imaging + follow-up |
Popular Clinics in Korea
- B&VIIT Eye Center (Seoul)
- Dream Eye Center (Seoul)
- BGN Eye Clinic (Seoul & Busan)
- Glory Seoul Eye Clinic
- Kim’s Eye Hospital (Seoul)
- NUNE Eye Hospital (Daegu)
- Seoul National University Hospital Retina Center
- Gangnam Severance Hospital Ophthalmology
